Papers/PMID:36482258
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.
GeroScience2023The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
NMN zwitterion — no detected effect on HOMA-IR
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The HOMA-IR showed no statistically significant differences for all NMN-treated groups as compared to placebo at day 60.”
Quoted verbatim from The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.. - Study
- RCT
- Duration
- 2 months
- Dose
- 300, 600 or 900 mg NMN once daily orally for 60 days
- Population
- Healthy middle-aged adults in a randomized, multicenter, double-blind, placebo-controlled, parallel-group trial; 300, 600 and 900 mg NMN groups each compared with placebo at day 60
The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial.2023PMID:36482258Permalink